Meeder Asset Management Inc Biocryst Pharmaceuticals Inc Transaction History

Meeder Asset Management Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 11, 2020	SELL	$1.9 - $5.61 $1,928 - $5,694	-1,015 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$1.6 - $4.11 $665 - $1,709	416 Added 69.45%	1,015 $2,000
Q4 2019 Feb 13, 2020	BUY	$1.59 - $3.45 $952 - $2,066	599 New	599 $2,000
Q3 2019 Oct 17, 2019	SELL	$2.5 - $3.73 $5,535 - $8,258	-2,214 Closed	0 $0
Q2 2019 Aug 05, 2019	BUY	$2.91 - $9.15 $6,442 - $20,258	2,214 New	2,214 $8,000
Q1 2019 Apr 16, 2019	SELL	$7.38 - $9.72 $5,800 - $7,639	-786 Closed	0 $0
Q4 2018 Jan 17, 2019	BUY	$6.51 - $9.6 $5,116 - $7,545	786 New	786 $6,000

279

172M

625K

739K

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.41B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

Get notified when there are updates to the investment portfolio of Meeder Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Meeder Asset Management Inc with notifications on news.